Oxidative stress in systemic lupus erythematosus: relationship to disease activity and symptoms

Abstract

Oxidative stress may play a role in the pathogenesis of systemic lupus erythematosus (SLE). We examined the hypothesis that oxidative stress was associated with indices of lupus disease activity and severity of symptoms. Urinary F₂ isoprostane excretion, a validated marker of oxidative stress, was measured in 95 patients with SLE and 103 healthy controls. Outcome measures included SLEDAI and SLICC scores, the modified health assessment questionnaire, the fatigue severity scale (FSS), and visual analogue scales (VAS) for fatigue, pain and overall disease activity. F₂ isoprostane excretion was compared in patients and controls, and its relationship with clinical variables in SLE examined. F2 isoprostane excretion did not differ significantly among patients with lupus (2.7 ± 2.3 ng/mg Cr) and control subjects (2.2 ± 1.4 ng/mg Cr) (P = 0.70). In patients with lupus, F₂ isoprostane concentrations were independently associated with higher patient reported disease activity (VAS) (OR = 1.52, P = 0.01), fatigue (FSS, OR = 1.52, P = 0.03) and lower quality of life (OR = 0.73, P = 0.05), but not with objective markers or inflammation or disease activity. In conclusion, F₂ isoprostane excretion is associated with patient-reported symptoms in SLE but not with measures of inflammation, SLEDAI or SLICC. Oxidative stress may contribute to debilitating symptoms such as fatigue in SLE.

Keywords

isoprostanes oxidative stress systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Abu-Shakra M , Urowitz MB , Gladman DD , Gough J . Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995; 22: 1259–1264.

Ames PR , Alves J , Murat I , Isenberg DA , Nourooz-Zadeh J . Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement. Rheumatology (Oxford) 1999; 38: 529–534.

Nuttall SL , Heaton S , Piper MK , Martin U , Gordon C . Cardiovascular risk in systemic lupus erythematosus–evidence of increased oxidative stress and dyslipidaemia. Rheumatology (Oxford) 2003; 42: 758–762.

Ceconi C , Boraso A , Cargnoni A , Ferrari R . Oxidative stress in cardiovascular disease: myth or fact? Arch Biochem Biophys 2003; 420: 217–221.

Young IS , Woodside JV . Antioxidants in health and disease. J Clin Pathol 2001; 54: 176–186.

Morrow JD , Chen Y , Brame CJ et al. The isoprostanes: unique prostaglandin-like products of free-radical-initiated lipid peroxidation. Drug Metab Rev 1999; 31: 117–139.

Davi G , Ciabattoni G , Consoli A et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224–229.

Davi G , Di Minno G , Coppola A et al. Oxidative stress and platelet activation in homozygous homocystinuria. Circulation 2001; 104: 1124–1128.

Davi G , Guagnano MT , Ciabattoni G et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002; 288: 2008–2014.

10.

Davi G , Alessandrini P , Mezzetti A et al. In vivo formation of 8-epi-prostaglandin F2 alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17: 3230–3235.

11.

Stein CM , Tanner SB , Awad JA , Roberts LJ , Morrow JD . Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 1996; 39: 1146–1150.

12.

Morrow JD , Frei B , Longmire AW et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995; 332: 1198–1203.

13.

Taysi S , Gul M , Sari RA , Akcay F , Bakan N . Serum oxidant/antioxidant status of patients with systemic lupus erythematosus. Clin Chem Lab Med 2002; 40: 684–688.

14.

Iuliano L , Pratico D , Ferro D et al. Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies. Blood 1997; 90: 3931–3935.

15.

Soep JB , Mietus-Snyder M , Malloy MJ , Witztum JL , von Scheven E . Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric-onset systemic lupus erythematosus. Arthritis Rheum 2004; 51: 451–457.

16.

Wang ZQ , Porreca F , Cuzzocrea S et al. A newly identified role for superoxide in inflammatory pain. J Pharmacol Exp Ther 2004; 309: 869–878.

17.

Vecchiet J , Cipollone F , Falasca K et al. Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. Neurosci Lett 2003; 335: 151–154.

18.

Asanuma Y , Oeser A , Shintani AK et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407–2415.

19.

Oeser A , Chung CP , Asanuma Y , Avalos I , Stein CM . Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 3651–3659.

20.

Asanuma Y , Chung CP , Oeser A et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 2006; 33: 539–545.

21.

Morrow JD , Roberts LJ . Mass spectrometry of prostanoids: F2-isoprostanes produced by non-cyclooxygenase free radical-catalyzed mechanism. Methods Enzymol 1994; 233: 163–174.

22.

Pincus T , Summey JA , Soraci SA Jr , Wallston KA , Hummon NP . Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983; 26: 1346–1353.

23.

Bombardier C , Gladman DD , Urowitz MB , Caron D , Chang CH . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630–640.

24.

Gladman DD , Urowitz MB , Goldsmith CH et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 809–813.

25.

Krupp LB , LaRocca NG , Muir-Nash J , Steinberg AD . The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121–1123.

26.

Spitzer WO , Dobson AJ , Hall J et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 1981; 34: 585–597.

27.

Harrel FE . Regression modeling strategies. Springer, 2001.

28.

Baraldi E , Carraro S , Alinovi R et al. Cysteinyl leukotrienes and 8-isoprostane in exhaled breath condensate of children with asthma exacerbations. Thorax 2003; 58: 505–509.

29.

Hahn BH . Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med 2003; 349: 2379–2380.

30.

Tench CM , McCurdie I , White PD , D'Cruz DP . The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology (Oxford) 2000; 39: 1249–1254.

31.

Omdal R , Mellgren SI , Koldingsnes W , Jacobsen EA , Husby G . Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics. J Rheumatol 2002; 29: 482–486.

32.

Smirnova IV , Pall ML . Elevated levels of protein carbonyls in sera of chronic fatigue syndrome patients. Mol Cell Biochem 2003; 248: 93–95.

33.

Evans AR , Junger H , Southall MD et al. Isoprostanes, novel eicosanoids that produce nociception and sensitize rat sensory neurons. J Pharmacol Exp Ther 2000; 293: 912–920.